36 filings
8-K
VTAE
Vitae Pharmaceuticals Inc
25 Oct 16
Termination of a Material Definitive Agreement
12:00am
8-K
VTAE
Vitae Pharmaceuticals Inc
14 Sep 16
Entry into a Material Definitive Agreement
12:00am
8-K
VTAE
Vitae Pharmaceuticals Inc
3 Aug 16
Vitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results
12:00am
8-K
VTAE
Vitae Pharmaceuticals Inc
27 Jul 16
Vitae Pharmaceuticals Appoints Daniel M. Junius to Board of Directors
12:00am
8-K
VTAE
Vitae Pharmaceuticals Inc
30 Jun 16
Entry into a Material Definitive Agreement
12:00am
8-K
l89laxy6ec3b7ww8v1u
26 May 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
3jwsbm6r8rodoj35jod
10 May 16
Vitae Pharmaceuticals Reports First Quarter 2016 Operating and Financial Results
12:00am
8-K
p642b1dn
24 Mar 16
Vitae Pharmaceuticals Prices Public Offering of Common Stock
12:00am
8-K
ork0t0
23 Mar 16
Vitae Pharmaceuticals Proposes Public Offering of Common Stock
12:00am
8-K
mlellio
16 Mar 16
Regulation FD Disclosure
12:00am
8-K
xu4tzvm6w
3 Mar 16
Vitae Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Operating and Financial Results
12:00am
8-K
cvv2534v7l69v82wy
17 Dec 15
Termination of a Material Definitive Agreement
12:00am
8-K
jyxw0ceo
10 Dec 15
Other Events
12:00am
8-K
8hbj79
19 Nov 15
Regulation FD Disclosure
12:00am
8-K
ad3k3
18 Nov 15
Vitae Pharmaceuticals Announces Positive Top-Line Results from a Phase 1 Multiple Ascending Dose Trial of VTP-43742
12:00am
8-K
2v6pws
5 Nov 15
Vitae Pharmaceuticals Reports Third Quarter 2015 Operating and Financial Results
12:00am
8-K
kyy2t81bdtibnu8
30 Sep 15
Vitae Pharmaceuticals Appoints Dr. Karen Bernstein to Board of Directors
12:00am
8-K
bf5kz0heqf zh
29 Sep 15
Other Events
12:00am
8-K
ygfc6
8 Sep 15
Other Events
12:00am
8-K
7jbp7exxl8xpio
10 Aug 15
Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders
12:00am